News6 months ago
There’s a ‘bearish-to-bullish’ reversal happening in this biotech stock, says Carter Worth
Large-cap biotech Regeneron Pharmaceuticals is judged to be in the throes of a “bearish-to-bullish” reversal, with the prospective completion of the bottoming-out process implying a move to...